PatientsVille.com Logo


Tumor Medical Research Studies

Up-to-date List of Tumor Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Tumor Medical Research Studies

Rank Status Study
1 Recruiting Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Conditions: Sarcoma;   Melanoma;   Epithelial Malignancies;   Pleural Malignancy
Interventions: Biological: Epigenetically Modified Autologous Tumor;   Drug: Cyclophosphamide;   Drug: Celecoxib
Outcome Measures: To assess the safety of an epigenetically modified autologous Tumor cell vaccine administered with ISCOMATRIX adjuvant in combination with metronomic oral cyclophosphamide and celecoxib in patients undergoing thoracic metastasectomy.;   To ascertain if autologous epigenetically modified Tumor cell vaccines induce immunity to CTAs in patients following thoracic metastasectomy.;   To assess feasibility, reliability, and reproducibility of establishing Tumor lines from patients with thoracic malignancies;   To examine effect of oral metronomic CP + celecoxib in number of T regs.
2 Recruiting Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
Conditions: Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IV Breast Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Other: cytology specimen collection procedure;   Other: laboratory biomarker analysis
Outcome Measures: Feasibility of NGS on metastatic solid Tumor tissue, in terms of number of patients screened, FMI test attempted, FMI test successful, and FMI tests results released to physicians;   Feasibility of NGS result-based non-FDA-approved treatment plan, measured by reasons for ability or inability to receive an anti-cancer agent;   Availability of recommended experimental regimens via clinical trials;   Proportion of patients who have one recommended therapy;   Proportion of patients who have multiple options recommended;   Presence of any oncogene or Tumor suppressor gene mutations or amplifications identified by NGS on Tumor tissue in each cohort
3 Recruiting Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy
Conditions: Solid Tumors;   Hematologic Cancers
Intervention: Other: molecular profiling of Tumors
Outcome Measures: frequency of "actionable" oncogenic mutations;   To determine the impact of molecular profiling results performed in the CLIA-setting on the treatment of patients.;   interrogate the mechanisms;   To explore the genetic mechanisms of Tumorigenesis
4 Recruiting Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Conditions: Lung Cancer;   Esophageal Cancer;   Malignant Pleural Mesothelioma;   Sarcoma;   Thymic Carcinoma
Interventions: Biological: Allogeneic Tumor Cell Vaccine (K562);   Drug: Celecoxib;   Drug: cyclophosphamide
Outcome Measures: Tabulation of toxicity type and grade;   To ascertain if K526-GM vaccines induce immunity to CT antigens commonly expressed in thoracic malignancies.;   To determine if metronomic oral CP and celecoxib reduce the number, percentage and function of CD4+ CD25+ Fox P3+ regulatory T cells (T reg) in peripheral blood of thoracic oncology patients.
5 Recruiting Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum
Conditions: Sarcoma;   Melanoma;   Epithelial Malignancies;   Pleural Malignancies
Intervention: Biological: Allogenic Tumor Cell Vaccine (K562)
Outcome Measures: To assess the safety of K562-GM allogeneic Tumor cell vaccines in combination with oral metronomic cyclophosphamide and celecoxib in patients undergoing thoracic metastasectomy.;   Ascertain if K562-GM cell vaccines induce immunity to CTAs in patients following thoracic metastasectomy.;   To examine if oral metronomic CP and celecoxib therapy reduces the number, activity and percentage of T regs cells in this patient population.
6 Recruiting Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
Conditions: Glioma;   Brain Cancer;   Brain Tumor;   Glioblastoma Multiforme;   High Grade Glioma
Interventions: Biological: Dendritic Cell Vaccine;   Biological: Tumor Lysate;   Other: Imiquimod;   Procedure: Punch Biopsy of the Skin;   Procedure: Leukapheresis
Outcome Measures: Number of Subjects Experiencing Adverse Events;   Number of Subjects Experiencing Complete Response or Partial Response according to RECIST Criteria 1.1;   Measurement levels of Myeloid Derived Suppressor Cells before and after treatment;   Number of Patients with Recurrent Brian Tumor who complete Therapy
7 Not yet recruiting SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
Condition: Metastatic Colorectal Cancer
Interventions: Drug: CY;   Biological: GVAX;   Drug: SGI-110
Outcome Measures: Difference in CD45RO+ Tumor infiltrating lymphocytes (TILs) measured by immunohistochemistry in pre and post-treatment Tumor biopsies from patients with metastatic colorectal cancer;   Number of Participants with Adverse Events as a Measure of Safety and Tolerability;   Overall Survival (OS);   Time To Progression (TTP);   Progression Free Survival (PFS)
8 Recruiting Germ Cell Tumor and Testicular Tumor DNA Registry
Conditions: Germ Cell Tumor;   Testicular Tumor
Interventions: Behavioral: Questionnaires;   Other: sample of blood or saliva
Outcome Measure: creation of a Germ Cell Tumor and testicular Tumor registry
9 Recruiting Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Conditions: Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Extrapulmonary Small Cell Cancer;   Pulmonary Neuroendocrine Tumors;   Thymic Epithelial Tumors
Outcome Measures: Allow sample acquisition for use in the study of thoracic malignancies except mesothelioma.;   Follow the natural history of patients with thoracic malignancies.;   Conduct genomic, proteomic and immunological analyses on blood, Tumor, body fluid and normal tissue in support of NIH translational trials to develop new therapeutic agents and novel treatment approaches as well as new prognostic and diagnostic ...
10 Recruiting Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention: Procedure: Tumor Debulking Surgery (surgery in recurrent ovarian disease)
Outcome Measures: Overall survival in patients with platinum-sensitive recurrent ovarian cancer with a positive AGO-score;   Quality of Life;   Progression free survival
11 Unknown  Early Detection of Cancers in Low Resource Countries
Conditions: Breast Neoplasms;   Uterine Cervical Neoplasms;   Ovarian Neoplasms;   Endometrial Neoplasms
Interventions: Procedure: Breast Cancer Screening and Diagnosis;   Procedure: Cervical Cancer Screening and Diagnosis;   Procedure: Ovarian Cancer Screening and Diagnosis;   Procedure: Endometrial Cancer Screening and Diagnosis
Outcome Measures: The Effectiveness of an Innovative, Low-Cost Screening and Diagnostic Methodology;   Effectiveness of CBE and Ultrasonography for Breast Cancer Detection
12 Recruiting Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
Conditions: Malignant Solid Tumour;   Breast Cancer Nos Metastatic Recurrent;   Neuropathy
Intervention: Drug: Eribulin in Combination w/ Cyclophosphamide
Outcome Measures: Phase Ib: 1. Maximum tolerated dose (MTD) of eribulin in combination with cyclophosphamide in patients with any solid Tumor;   Phase II 1. Clinical benefit (complete response, partial response, and stable disease) of the combination of eribulin and cyclophosphamide in patients with advanced breast cancer;   Phase Ib: 1. Safety of treatment;   Phase Ib: 2. Dose Limiting Toxicity (DLT);   Phase Ib: 3. Pharmacokinetics (PK) and potential for drug-drug interaction;   Phase Ib: 4. Quality of life;   Phase Ib: 5. Pharmacodynamic, pharmacogenomic and response prediction biomarkers;   Phase II 1. Efficacy of drug combination in patients with advanced breast cancer including response rate, duration of response and time to progression;   Phase II 2. Safety of drug combination in expanded cohort - metastatic breast cancer;   Phase II 3. Quality of life endpoints;   Phase II 4. Pharmacodynamic, pharmacogenomic and response prediction biomarkers
13 Recruiting Genomic Testing for Primary Breast Cancer
Condition: Breast Cancer
Interventions: Procedure: Tumor Biopsy;   Other: Breast Cancer Registry
Outcome Measure: Feasibility Analysis of Genomic Predictor from Localized Invasive Breast Cancer Tumor Registry
14 Recruiting Evaluate Risk/Benefit of Nab Paclitaxel in Combinaton With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Conditions: Breast Tumor;   Breast Cancer;   Cancer of the Breast;   Estrogen Receptor- Negative Breast Cancer;   HER2- Negative Breast Cancer;   Progesterone Receptor- Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Triple-negative Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects;   Drug: Carboplatin AUC 2;   Drug: gemcitabine 1000 mg
Outcome Measures: Progression Free Survival (PFS) for triple negative metastatic breast cancer subjects (Phase 2);   Progression Free Survival (PFS) for triple negative metastatic breast cancer subjects (Phase 3);   Investigator-determined Overall Response Rate (ORR) (Phase 2);   Percentage of subjects who initiated Cycle 6 receiving doublet combination therapy (Phase 2);   Investigator determined Overall Survival (OS) for triple negative metastatic breast cancer (TNMBC) subjects (Phase 2);   Safety for triple negative metastatic breast cancer (TNMBC) subjects (Phase 2);   Independent blinded radiologists-determined Overall Response Rate (ORR) (Phase 3);   Overall Survival (OS) for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3);   Compare disease control rate for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3);   Duration of Response for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3);   Safety of each treatment regimen for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3);   Investigator assessed Progression Free Survival (PFS)for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3);   Incidence of subjects experiencing dose modifications (dose interruptions and reductions);;   Percentage of subjects who discontinued from all study treatment adverse event
15 Recruiting Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
Conditions: Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dovitinib lactate;   Drug: gemcitabine hydrochloride;   Drug: capecitabine;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Other: pharmacological study
Outcome Measures: Maximum tolerated dose (MTD) is defined as the highest dose level at which less than 33% of patients experience study treatment-related dose limiting toxicities (DLT);   Overall safety profile characterized by type, frequency, severity (according to National Cancer Institute [NCI] CTCAE version 4.0), timing, seriousness and relationship to study treatment;   Plasma pharmacokinetic parameters of dovitinib lactate, gemcitabine hydrochloride, capecitabine and their metabolites;   Solid Tumor/dose-finding cohort: response rate, progression free survival;   Pancreas cancer cohort: survival, response rate and progression free survival;   Pharmacodynamic effects of dovitinib lactate and Gem-Cap combination on vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptors (FGFR) dynamics in serum and Tumor specimens
16 Recruiting PET/CT-Assessment of Liver Tumor Ablation
Conditions: Liver Tumor;   Liver Neoplasms
Interventions: Radiation: N-13 ammonia;   Device: PET/CT scanner
Outcome Measures: Number and percentage of Tumors with complete, circumferential ablation margin visibility during FDG PET/CT-guided liver ablations (AP-PET-1 v. CECT);   Number and percentage of Tumors with complete, circumferential ablation margin visibility during FDG PET/CT-guided liver ablations (AP-PET-1 v. PET/CECT);   Ablation Margin Assessment: Percentage Adequate or Not Adequate;   Non-FDG-Avid Tumors- Percentage of Tumors with complete, circumferential ablation margin visibility during FDG PET/CT-guided liver ablations;   Ablation margin assessment of non-FDG-avid Tumors: concordance rate of AP-PET fused to pre-procedural MRI v. 24-hour post-procedure MRI or CT;   FDG-Tumor-Tumor Rate Progression
17 Recruiting Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Conditions: Carcinoma, Non-Small-Cell Lung;   Carcinoma, Small Cell Lung;   Carcinoma, Thymic
Interventions: Drug: AZD;   Drug: MK-2206;   Drug: Lapatinib;   Drug: Erlotinib;   Drug: Sunitinib;   Procedure: Molecular Profiling
Outcome Measures: To determine the feasibility of the use of Tumor s molecular profiling and targeted therapies in the treatment of NSCLC, SCLC, and Thymic Malignancies;   To estimated the response rate of molecular-profile directed treatments in NSCLC, SCLC, and Thymic Malignancies;   To determine Progression Free Survival, duration of response, and overall survival;   To evaluate changes in the Tumor s molecular profile on serial biopsies when patients progress after an initial response to treatment.;   To identify molecular profiles in patients with NSCLC, SCLC, and Thymic Malignancies
18 Recruiting Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Conditions: Cervical Cancer;   Endometrial Cancer;   Fallopian Tube Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2);   Ovarian Cancer;   Sarcoma;   Uterine Leiomyomata;   Vaginal Cancer;   Vulvar Cancer
Interventions: Other: laboratory biomarker analysis;   Other: screening questionnaire administration;   Procedure: study of high risk factors
Outcome Measures: Identification and development of highly sensitive and specific Tumor markers for the detection and management of ovarian cancer and other gynecological malignancies;   Identification of new prevention approaches and therapies;   Identification of measures to improve the quality of life for women at increased risk for developing the disease and for women diagnosed with ovarian cancer
19 Recruiting A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers
Conditions: Breast Cancer;   Lung Cancer;   Renal Cancer;   Adrenal Cancer
Intervention: Drug: F-18 Paclitaxel (FPAC)
Outcome Measures: Determine if the FPAC uptake in Tumors is different than the uptake in normal background tissues; Determine safety of FPAC administration;   Compare FPAC uptake with FDG uptake in solid Tumors; make preliminary comparisons of FPAC uptake with treatment response and drug transporter expression when available
20 Recruiting Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Condition: Neoplasms
Intervention: Genetic: Blood and Tumor samples
Outcome Measures: Establish a map of genetic profiles (for the pre-identified target genes) for all types of advanced malignant Tumors.;   Establish a map of immunologic profiles for all types of advanced malignant Tumors.;   Determine for each histological type of Tumor, characteristic profiles of genetic and/or immunologic disorders and disorders that might be common to several histological types.;   Identify genetic and/or immunologic biomarkers (or molecular profiles) with a potential predictive value on response to treatments.;   Identify biomarkers (constitutional or somatic alterations in Tumor cells) that might be correlated with systemic or local alterations of the immunity status observed in some patients with advanced cancers;   Assess the changes of genetic and/or immunologic profiles in case of progressive disease

These studies may lead to new treatments and are adding insight into Tumor etiology and treatment.

A major focus of Tumor research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Tumor